Rocket Lab’s Two Realities: A $2.2 Billion Backlog Meets a 62% Rout

Rocket Lab's record contracts and rapid launches clash with a 61% stock drop, as Neutron rocket delays and sector turmoil weigh on investor sentiment.

The numbers coming out of Rocket Lab these days tell two completely different stories. On one side sits a $2.2 billion contract backlog, a fresh $266 million Space Force deal, and a record-breaking launch that put a satellite in orbit within 17 hours. On the other sits a stock that has shed 61.73% of its value since late May, closing Wednesday at €51.20 — a level that has the 14-day RSI flashing oversold at 29.2.

The disconnect is stark, and it’s forcing investors to decide which narrative matters more.

The Neutron Question Hangs Over Everything

The most immediate weight on the share price isn’t a lack of business — it’s the engineering challenge sitting in Mississippi. At NASA’s Stennis Space Center, Rocket Lab is putting its Archimedes engine through its paces for the upcoming Neutron rocket, a vehicle designed to go head-to-head with SpaceX’s Falcon 9. A full-duration burn of the second stage on July 14 marked real progress, but the market hasn’t forgotten the manufacturing defect earlier this year that caused a fuel tank to rupture during a static-fire test.

With Neutron’s first launch penciled in for the fourth quarter of 2026, any doubt about that timeline is punishing the valuation. The narrative has shifted from “the next SpaceX” to the sobering reality of rocket development, where setbacks are expensive and delays compound quickly.

A $266 Million Win That Can’t Stop the Bleeding

The irony is that Rocket Lab’s operational momentum has rarely been stronger. On July 27, the US Space Force awarded the company a record $266 million contract for 12 suborbital launches from the Pacific Spaceport Complex on Kodiak, Alaska, with an option for six more. Alaska Aerospace, which has operated the site since 1991 and logged 34 launches to date, will host the missions starting in late 2026.

That win followed an $89.5 million contract for Rocket Lab’s first-ever geostationary satellite order — two spacecraft that push the company into an entirely new market segment. And just days earlier, the company demonstrated its rapid-response capability under the TacRS program: an Electron rocket carrying its own Pioneer satellite reached orbit just 16 hours and 42 minutes after receiving the launch order, a new speed record for the Space Force.

The broader contract pipeline now exceeds $2.2 billion, with first-quarter revenue hitting a record $200.3 million. Rocket Lab has also deepened its ties to the defense establishment as a supplier to Raytheon on the Space Based Interceptor program, embedding its propulsion and bus technology into the US missile defense architecture.

Sector Contagion and the Iridium Overhang

So why is the stock getting hammered? Part of the answer lies outside Rocket Lab’s control. The broader space sector is in turmoil: SpaceX shares, which have fallen sharply since their IPO, have triggered a wave of selling across the industry that has swept up Rocket Lab along with it. A proposed FAA rule change that could eliminate environmental reviews for rocket launches — a potentially significant regulatory win — failed to stem the tide.

Then there’s the Iridium factor. Rocket Lab’s roughly $8 billion acquisition of the satellite operator, financed through a $3.6 billion bridge loan, has introduced a new layer of financial complexity that some investors are still digesting. Cathie Wood’s ARK Invest signaled its own view of the shifting landscape on July 28, buying roughly 62,500 Rocket Lab shares worth about $4 million while trimming its Iridium position by nearly 185,000 shares valued at $8.4 million — a portfolio rebalancing that reflects the coming merger.

Analysts See a Mispriced Opportunity

The technical picture suggests the selling may be overdone. With the RSI deep in oversold territory, historical patterns indicate that selling pressure tends to ease at these levels. The analyst consensus backs that up: the average price target stands at €100.40, roughly double the current share price, implying the market is pricing in near-term test risks rather than the long-term infrastructure bet.

Rocket Lab’s first-quarter loss of $0.07 per share beat the consensus estimate of -$0.08, and the next quarterly report is due August 10. That release will offer the first glimpse of whether the Kodiak contract, the GEO satellite business, and the Iridium integration are beginning to show up in the financials.

For now, the stock remains caught between two forces: an operating business that keeps winning and a market that keeps selling. The Neutron first launch later this year will likely determine which side breaks first.